Your browser is no longer supported. Please, upgrade your browser.
Settings
MBRX Moleculin Biotech, Inc. daily Stock Chart
MBRX [NASD]
Moleculin Biotech, Inc.
Index- P/E- EPS (ttm)-0.51 Insider Own25.51% Shs Outstand28.26M Perf Week5.19%
Market Cap40.13M Forward P/E- EPS next Y-0.41 Insider Trans0.00% Shs Float20.19M Perf Month12.70%
Income-12.30M PEG- EPS next Q-0.10 Inst Own7.50% Short Float5.97% Perf Quarter2.16%
Sales- P/S- EPS this Y-32.20% Inst Trans-26.03% Short Ratio3.33 Perf Half Y-16.47%
Book/sh0.56 P/B2.54 EPS next Y12.80% ROA-54.90% Target Price5.50 Perf Year-24.06%
Cash/sh0.30 P/C4.67 EPS next 5Y- ROE-70.70% 52W Range0.93 - 3.34 Perf YTD36.54%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.49% Beta-
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin- 52W Low52.03% ATR0.11
Employees2 Current Ratio3.00 Sales Q/Q- Oper. Margin- RSI (14)63.01 Volatility6.32% 8.22%
OptionableNo Debt/Eq0.00 EPS Q/Q45.60% Profit Margin- Rel Volume0.19 Prev Close1.37
ShortableYes LT Debt/Eq0.00 EarningsFeb 12 BMO Payout- Avg Volume361.99K Price1.42
Recom2.00 SMA2020.31% SMA5013.03% SMA200-10.08% Volume68,746 Change3.65%
Dec-20-17Initiated ROTH Capital Buy $8
Jan-09-19 07:30AM  Moleculin Announces Patient Recruitment Begins in Annamycin Clinical Trial In Poland GlobeNewswire
Jan-07-19 10:06AM  Amarin Down on Lower '19 View, Posts Preliminary '18 Results Zacks +5.69%
Jan-03-19 07:30AM  Moleculin Announces Positive Data for its Pancreatic Cancer Drug Candidate GlobeNewswire
Dec-31-18 07:30AM  Report: Exploring Fundamental Drivers Behind Cronos Group, Henry Schein, Argo Group International, Eiger BioPharmaceuticals, China Automotive, and Moleculin Biotech New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Dec-12-18 06:55AM  Today's Research Reports on Trending Tickers: NeuroMetrix and Moleculin ACCESSWIRE
Dec-11-18 07:30AM  REMINDER: Moleculin Announces Conference Call to Discuss Recent Breakthrough Discovery and FDA Filing on Wednesday, December 12, 2018 GlobeNewswire +18.70%
Dec-06-18 04:05PM  Moleculin Announces Conference Call to Discuss FDA Filing and New Immune Checkpoint Data on Wednesday, December 12, 2018 GlobeNewswire
07:30AM  Moleculin Announces FDA Filing for Orphan Drug Designation for Glioblastoma Drug GlobeNewswire
Dec-04-18 07:30AM  Moleculin Announces Breakthrough Discovery for its WP1066 GlobeNewswire
Nov-28-18 07:30AM  Moleculin Announces New Data Further Supporting Its Lead Drug for Treating Pancreatic Cancer GlobeNewswire
Nov-19-18 08:45AM  Consolidated Research: 2018 Summary Expectations for Moleculin Biotech, Novan, PAVmed, Maui Land & Pineapple, Hallmark Financial Services, and McEwen Mining Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-15-18 07:30AM  Moleculin Requests FDA Meeting Regarding IND for New Cancer Drug GlobeNewswire +8.66%
Nov-13-18 07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2018 GlobeNewswire
Nov-08-18 07:30AM  Moleculin Announces New Independent Study Expands Potential Use of Its Pancreatic Drug Candidate WP1122 GlobeNewswire +9.60%
Nov-01-18 07:30AM  Moleculin Announces Significant Milestone Achieved in Glioblastoma Trial GlobeNewswire +9.62%
Oct-25-18 07:30AM  Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials GlobeNewswire +5.17%
Oct-10-18 07:30AM  Moleculin Announces New Data Discovery Confirming Significant Increase in Potential to Starve Cancerous Tumors GlobeNewswire
Sep-13-18 07:30AM  Moleculins Brain Cancer Drug Candidate Begins Patient Dosing at Clinical Trial Being Conducted at MD Anderson GlobeNewswire
Aug-13-18 07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2018 GlobeNewswire
Aug-09-18 07:30AM  Moleculin Seeks Approval from Polish Regulatory Agency for Skin Cancer Clinical Trial GlobeNewswire
Jul-31-18 07:30AM  Moleculin Announces Enrollment Opens for Brain Tumor Trial of WP1066 GlobeNewswire
Jul-18-18 07:30AM  Moleculin Expects to Meet FDA IND Filing Requirements for its Pancreatic Cancer Drug Candidate with Development Work in Australia GlobeNewswire
Jul-11-18 07:30AM  Moleculin Expands Operations to Australia; Taps R&D Incentive Program Capped at $20,000,000 AUD Turnover GlobeNewswire
Jun-26-18 07:30AM  Moleculin Selected for the Russell Microcap Index GlobeNewswire
Jun-21-18 07:30AM  Moleculin Announces $2.3 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -13.82%
Jun-20-18 08:52AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +7.96%
07:30AM  Moleculin Receives Approval for Leukemia Clinical Trial GlobeNewswire
Jun-12-18 07:30AM  Moleculin Targets accelerated FDA approval of WP1732; Pursues Development for Ocular Tumors GlobeNewswire +6.45%
Jun-06-18 09:09AM  Moleculins Breakthrough Discovery of a New Molecule for Cancer Treatment Advances to Development Agreement with the University of Iowa GlobeNewswire
May-29-18 07:20AM  Nektar Therapeutics and Three Additional Biotech Stocks on Our Research Desks Radar ACCESSWIRE
May-24-18 08:30AM  Moleculin Invited to Present to International BioForum 2018 Conference GlobeNewswire
May-18-18 12:43PM  Who Owns Most Of Moleculin Biotech Inc (NASDAQ:MBRX)? Simply Wall St.
May-16-18 08:30AM  Moleculin to Begin Clinical Trials at UMC Southwest Cancer Center GlobeNewswire
May-15-18 08:30AM  Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2018 GlobeNewswire
May-03-18 08:30AM  Moleculin Announces Engagement with Voisin Consulting Life Sciences to Expand Annamycin Clinical Trial GlobeNewswire
Apr-26-18 08:30AM  Moleculin Announces New Data for Immuno-Stimulating Drug to be Presented at International Conference Marketwired
Apr-12-18 07:00AM  Wired News Spectrum Pharma Reported Update Data from MD Andersons Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients ACCESSWIRE
Apr-04-18 08:30AM  Moleculin Announces Patients Treated in FDA Approved Phase I/II Annamycin Clinical Trial Marketwired
Mar-28-18 08:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2017 Marketwired
Mar-27-18 08:30AM  Moleculin Enters Agreement with Seidman Cancer Center to Conduct Leukemia Clinical Trials Marketwired
Mar-20-18 08:30AM  Moleculin Announces Grant-Funded Collaboration to Expand Understanding of New Discovery Marketwired
Mar-06-18 08:30AM  Moleculin to Present at the 30th Annual ROTH Conference Tuesday, March 13, 2018 Marketwired
Mar-02-18 10:03AM  The Market In 5 Minutes: Trump, Tariffs, Trade Wars And More Benzinga +5.82%
Mar-01-18 05:06PM  ICYMI: Snapchat, Molecular Biotech's CEO Speaks, SEC Examines Crypto ICOs Benzinga -5.03%
Feb-28-18 10:05AM  Reminder: Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018 Marketwired
Feb-22-18 08:30AM  Moleculin Announces Conference Call to Discuss Recent Discovery of New Molecule and Business Update on Wednesday, February 28, 2018 Marketwired
Feb-16-18 02:31PM  Heres Why Moleculin Biotech Inc (MBRX) Is Down Big Today SmarterAnalyst -26.07%
01:20PM  Moleculin Biotech's Volatility, Explained Benzinga
08:28AM  Moleculin Announces Pricing of $9 Million Registered Direct Offering Marketwired
Feb-15-18 10:57AM  Moleculin Biotech's stock rockets after 'major breakthrough' in cancer treatment MarketWatch +53.85%
08:30AM  Moleculin Announces Breakthrough Discovery of a New Molecule for Cancer Treatment Marketwired
Feb-13-18 08:30AM  Moleculin Announces Collaboration with Emory University to Develop Novel Treatment of Pediatric Brain Cancer Marketwired
Feb-07-18 08:30AM  Moleculin Announces Activity with Pancreatic Cancer Drug Marketwired
Jan-17-18 08:30AM  Leading Leukemia Experts Join Moleculin's Science Advisory Board Marketwired
Jan-10-18 08:30AM  Moleculin Expands Leukemia Development Portfolio with Immuno-Stimulating STAT3 Inhibitor Marketwired
Dec-21-17 08:30AM  Moleculin Announces Polish Approval for Leukemia Clinical Trial Marketwired
Dec-06-17 10:01AM  Moleculin's WP1066 Drug receives $2 million Private Grant Marketwired -9.13%
08:10AM  Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Moleculin Biotech ACCESSWIRE
Dec-05-17 07:00AM  Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance Marketwired +14.29%
Nov-28-17 03:06PM  Why Moleculin Biotech Incs (MBRX) Ownership Structure Is Important Simply Wall St.
Nov-21-17 07:30AM  Moleculin to Present at the 10th Annual LD Micro Main Event on December 5, 2017 at 11:30 a.m. PT Marketwired
Nov-14-17 07:00AM  Moleculin Biotech, Inc. Reports Financial Results for the Third Quarter Ended September 30, 2017 Marketwired
Nov-08-17 07:30AM  Moleculin Appoints Dr. Sandra Silberman as Chief Medical Officer -- New Products Marketwired
Nov-01-17 07:30AM  Moleculin Announces MD Anderson has Filed an IND with the FDA on its Drug WP1066 for the Treatment of Brain Tumors Marketwired
Oct-24-17 07:30AM  Moleculin Requests Authorization from the Polish Government to Advance Annamycin Marketwired -8.96%
Oct-18-17 07:30AM  Moleculin Announces 14 Qualified Clinical Sites Requesting Participation in Annamycin Trial Marketwired +7.94%
Oct-11-17 07:30AM  Moleculin Announces Strategic Collaboration to Develop Immune Stimulation Drug Marketwired
Oct-05-17 07:10AM  Corporate News Blog - Moleculin Biotech Signs Agreement with the First Hospital to Conduct Clinical Trials for Annamycin ACCESSWIRE
Oct-03-17 07:30AM  Moleculin Signs Agreement with First Hospital for Annamycin Trials Marketwired
Sep-28-17 07:50AM  Corporate News Blog - FDA Grants Approval to Moleculin Biotech for Clinical Trials of Annamycin in the Treatment of AML ACCESSWIRE
Sep-27-17 08:20AM  Today's Research Reports on Stocks to Watch: Axovant and Moleculin ACCESSWIRE -6.02%
Sep-26-17 07:00AM  Moleculin Announces FDA Approval of Annamycin IND Marketwired +10.37%
Sep-13-17 07:30AM  Moleculin Engages CRO to Begin Clinical Trials of WP1220 for the Treatment of Cutaneous T-Cell Lymphoma Marketwired
Sep-07-17 08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Verastem ACCESSWIRE
Sep-06-17 07:30AM  Moleculin to Collaborate on Combining its WP1122 Brain Cancer Drug Candidate with Roche's Drug Avastin Marketwired +7.20%
Aug-31-17 07:30AM  Moleculin Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference Marketwired
Aug-30-17 08:10AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech Inc. and GW Pharmaceuticals PLC ACCESSWIRE
Aug-29-17 07:30AM  Moleculin Announces Filing with FDA of IND for its Leukemia Drug Annamycin Marketwired +9.83%
Aug-24-17 07:00AM  Corporate News Blog - Moleculin Biotech to Meet European Medicines Agency; Discussion on Clinical Trial Authorization for the Treatment of Acute Myeloid Leukemia ACCESSWIRE
Aug-22-17 07:30AM  Moleculin Announces Meeting with European Medicines Agency Marketwired +5.68%
Aug-18-17 07:00AM  Featured Company News - Moleculin Biotech Acquires Active Drug Compound for the Treatment of Brain Cancer ACCESSWIRE -6.64%
Aug-16-17 07:30AM  Moleculin Acquires Active Drug Compound for the Treatment of Brain Cancer Marketwired +6.00%
Aug-14-17 08:00AM  Moleculin Updates Annamycin Progress, Analyst Coverage, Price Target and Full Pipeline Review ACCESSWIRE
07:30AM  Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2017 Marketwired
Aug-09-17 07:30AM  Moleculin Comments on Recent FDA Drug Approvals for Acute Myeloid Leukemia Marketwired +12.99%
Aug-03-17 07:30AM  Moleculin Begins Clinical Testing Site Development Efforts in Poland; Selects Bioscience SA as Polish CRO Marketwired +5.19%
Aug-01-17 09:25AM  3 Biotech Stocks to Watch in August ACCESSWIRE -9.36%
Jul-27-17 07:30AM  Moleculin Strengthens Board of Directors with Appointment of John M. Climaco Marketwired +8.26%
Jul-25-17 07:30AM  Moleculin's New Drug for the Treatment of Glioblastoma Nears Clinical Trials at MD Anderson Cancer Center Marketwired +7.49%
Jul-20-17 07:00AM  Featured Company News - Moleculin Biotech Signs License Agreement with MD Anderson Cancer Center for its Lead Product Candidate, Annamycin Accesswire
Jul-18-17 11:40AM  Tuesdays Wall Street News: Netflix, Inc. (NFLX), Capricor Therapeutics Inc (CAPR), Moleculin Biotech Inc (MBRX) SmarterAnalyst +20.59%
07:30AM  Moleculin Signs Agreement with MD Anderson Cancer Center for Leukemia Drug, Annamycin Marketwired
Jul-12-17 08:20AM  Today's Research Reports on Stocks to Watch: TherapeuticsMD, Inc. and Moleculin Biotech, Inc. Accesswire
07:30AM  Moleculin Regains Compliance with NASDAQ Listing Requirements Marketwired
Jul-06-17 07:30AM  Moleculin Appoints Lead European Principal Investigator for Planned Annamycin Clinical Trial Marketwired
Jun-29-17 07:30AM  Reminder: Moleculin Announces Conference Call to Discuss Recent New Discovery for Pancreatic Cancer and Business Update Marketwired -9.45%
Jun-28-17 08:15AM  Corporate News Blog - Moleculin Biotech Announces Scientific Support for Research Endeavor at Mayo Clinic Accesswire +65.66%
Jun-27-17 08:00AM  Today's Research Reports on Stocks to Watch: Moleculin Biotech and Conatus Pharmaceuticals Accesswire +30.26%
07:30AM  Moleculin Announces Conference Call to Discuss Recent New Discovery for Pancreatic Cancer and Business Update Marketwired
Jun-26-17 08:30AM  Biotech Stocks Showing Signs of Resurgence PR Newswire +38.18%
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.